China License Out

Announced Date: 2022-07-26 (July 26, 2022) Asset Name: SKB-264 (MK-2870) Licensor: Kelun-Biotech (subsidiary of Sichuan Kelun … [China BD deal 2022] Kelun-Biotech and MSD enters a 935 million USD license on  TROP2 ADC SKB-264Read more

Announced Date: 2022-06-13 ( June 13, 2022) Asset Name: Perjeta® (pertuzumab, HLX11) and Prolia®/Xgeva® (denosumab, HLX14). Licensor: Shanghai Henlius … [China BD 2022] Henlius and Organon enters a 471 billion USD license on two Biosimilar mAb Assets HLX11 and HLX14Read more

Announced Date: 2022-05-16 (May 16, 2022) Asset Name: SKB-315 (MK-1200) Licensor: Kelun-Biotech (subsidiary of Sichuan Kelun … [China BD deal 2022] Kelun-Biotech and MSD enters a 1.41 billion USD license on  Claudin18.2 ADC SKB-315(MK-1200)Read more

Announced Date: 2022-05-06 (May 6, 2022) Asset Name: JMKX000623 Licensor: Shanghai Jemincare Pharmaceutical (China) Licensee (Buyer): … [China BD 2022] Jemincare and Orion enters a license on NaV 1.8 blocker JMKX000623Read more

Announced Date: 2022-04-01 (April 01, 2024) Asset: GFH009 Licensor: GenFleet Therapeutics (China) Licensee (Buyer): SELLAS Life … [China BD 2022] GenFleet and SELLAS  enters a 150 million USD License on CDK9 inhibitor GFH009Read more

Announced Date: 2021-07-12 (July 12, 2021) Asset Name: Orelabrutinib Licensor (Seller): InnoCare Pharma (China) Licensee (Buyer): … [China BD 2021] Allist Pharma and ArriVent enters a 150 million USD License on EGFR TKI Orelabrutinib for the potential treatment of multiple sclerosis (MS)Read more

Announced Date: 2020-09-04 (September 04, 2020) Asset Name: Lemzoparlimab (TJC4) Licensor (Seller): I-MAB Biopharma (China) Licensee (Buyer): … [China BD 2020] I-Mab and Abbvie enters a License on anti-CD47 monoclonal antibody Lemzoparlimab (TJC4)Read more

Announced Date: 2020-06-01 (June 1, 2020) Asset Name: JAB-3068 and JAB-3312 Licensor (Seller): Jacobio Pharmaceuticals (China) … [China BD 2020] Jacobio and Abbvie enters a License on SHP2 inhibitors portfolioRead more